A researcher holding up a container of stem cells.Photo: Spencer Platt (Getty Images) A team of neurologists are raising a red flag over risky and unproven stem cell therapies. Their new study suggests that their fellow doctors are frequently asked about these controversial procedures by desperate patients. Many doctors are also seeing patients with serious complications from stem cell therapy, including seizures, infections, and spinal tumors
Cell Transplant Market Overview 2020 2025 This has brought along several changes in This report also covers the impact of COVID-19 on the global market.
Stem Cell Banking Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors
North America is expected to account for the largest share of the Biobanking Devices Market According to the new market research report "Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast" published by MarketsandMarkets The Biobanking Market is expected to reach $2.69 billion, at a CAGR of 7.8%.
Global Cell Isolation/Cell Separation Market was valued US$ XX Bn in 2018 and is expected to reach US$ 17.92 Bn by 2026, at a CAGR of around XX % during a forecast period.
Anand met with an unfortunate road accident and suffered spinal cord injury. He was suddenly propelled from the world of the able-bodied into the world of the disabled
By the time the FDA approved Luxturna the pioneering gene therapy for an inherited retinal disease Henry Klassen had been researching and treating the group of diseases known as retinitis pigmentosa for more than 20 years. Spark Therapeutics success there had not just inspired a $4.3 billion takeover by Roche, it had also emboldened other biotechs pursuing a therapy that would deliver one of the genes tied to different variations of the disorder. Nightstar Therapeutics subsequently scored its own buyout with Biogen, and MeiraGTx recently posted early but exciting data on its J&J-partnered program.
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cell viability assays market and it is poised to grow by USD 1.40 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19
In an industry where getting one drug developed from lab to clinic can cost hundreds of millions of dollars and decades of time, it helps when scientists can be thrifty and make use of substances that already exist. A global team of researchers has now done just that, by searching through one of the world's largest collections of already developed drugs to discover 21 potential treatments for COVID-19. We will need considerably more research to determine if any of these drugs can be used to help COVID-19 patients, but it's an excellent first step, bypassing some of the barriers for producing completely new drugs.
Translucently colored embryonic stem (ES) cell (upper right) and its differentiating derivatives (left and lower right).
Recent Comments